

Modified Form PTO-1449

Atty. Docket No.

A-451N

Serial No.

10/825,898

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

Applicant

Boyle

Filing Date

April 15, 2004

Group

**U.S. PATENT DOCUMENTS**

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	A1						
	A2						
	A3						
	A4						
	A5						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES <input type="checkbox"/> NO <input type="checkbox"/>
/R.S./	B1	0 784 093 A1	1997-07-16	EP			
	B2						
	B3						
	B4						

**OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)**

/R.S./	C1	Bharti and Aggarwal, "Ranking the role of RANK ligand in apoptosis", <i>Apoptosis</i> , 9: 677-690 (2004)
/R.S./	C2	Chopin et al., "Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21 waf1", <i>Exp. Cell Res.</i> , 298: 560-573 (2004)
/R.S./	C3	Collin et al., "Constitutive expression of osteoclast-stimulating activity by normal clonal osteoblast-like cells: effects of parathyroid hormone and 1,25-dihydroxyvitamin D3", <i>Endocrinology</i> , 131(3): 1181-1187 (1992)
/R.S./	C4	Lacey et al., "Interleukin 4, interferon-gamma, and prostaglandin E impact the osteoclastic cell-forming potential of murine bone marrow macrophages", <i>Endocrinology</i> , 136(8): 2367-2376 (1995)
	C5	Roitt et al., <i>Immunology</i> , 3rd Ed., MOSBY, ISBN: 0-397-44765-5, (1993)
/R.S./	C6	Takahashi et al., "Osteoblastic cells are involved in osteoclast formation", <i>Endocrinology</i> , 123(5): 2600-2602 (1996)
/R.S./	C7	Theill et al., "RANK-L and RANK: T Cells, Bone Loss, and Mammalian Evolution", <i>Annu. Rev. Immunol.</i> , 20: 795-823 (2002)
/R.S./	C8	Yasuda et al., "Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): A Mechanism by which OPG/OCIF Inhibits Osteoclastogenesis in Vitro", <i>Endocrinology</i> , 139(3): 1329-1337 (1998)
	C9	Amendment and Response to Office Action Mailed September 19, 2008, filed March 10, 2009 for USSN 10/408,901
	C10	Notice of Allowance and Fee(s) Due Mailed September 28, 2009 for USSN 10/408,901
	C11	Part B - Issue Fee(s) Transmittal filed December 22, 2009 for USSN 10/408,901

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modified Form PTO-1449

Atty. Docket No.

A-451N

Serial No.

10/825,898

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

Applicant

Boyle

Filing Date

April 15, 2004

Group

/R.S./	C12	Lacey et al., "Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation", Cell, 93: 165-176 (1998)
	C13	Response to Notice of Noncompliant Amendment and Preliminary Amendment filed August 21, 2009 for USSN 09/791,153
	C14	Office Communication Mailed September 2, 2009 for USSN 11/981,664
	C15	Response filed December 2, 2009 for USSN 11/981,664 including extension of time, electronic fee transmittal, and electronic acknowledgement receipt
	C16	Office Communication Mailed February 2, 2010 for USSN 11/981,664
	C17	Response filed February 16, 2010 for USSN 09/211,297 including exhibits A through H (Shown above in C9-C16), extension of time, IDS and SB08a Form, RCE transmittal, electronic fee transmittal and electronic acknowledgement receipt

EXAMINER:

/Ronald Schwadron/

Date Considered:

11/30/2010

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.